Double edged sword, great for OTC investors, not so much for OTC companies that rely on issuing shares to line insiders pockets or toxic funders. Perhaps over the next several months, we’ll see some of those depressed stocks work out of their rut as pressure is alleviated. If true, thanks for sharing! Rec